Stocks · News reference

Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target

Aug 13, 2026, 12:54 PMBenzinga Newsdesk

Wedbush analyst David Nierengarten reiterates Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $60 price target.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 13, 2026, 2:01 PMBenzinga Newsdesk
Citizens Maintains Market Outperform on Sutro Biopharma, Lowers Price Target to $34
Citizens analyst Reni J. Benjamin maintains Sutro Biopharma (NASDAQ:STRO) with a Market Outperform and lowers the price target from $41 to $34.
Read original at benzinga
STRO
BenzingaAug 12, 2026, 6:04 PMVandana Singh
Why is Sutro Biopharma Stock Falling On Wednesday?
Sutro Biopharma stock falls after its STRO-004 Phase 1 update, with DLTs reported at the highest dose and the next update planned for 2027.
Read original at benzinga
STRO
BenzingaAug 12, 2026, 4:16 PMAvi Kapoor
Gold Gains 1%; Performance Food Group Shares Fall After Q4 Results
Dow Jones up 0.1%, NASDAQ up 0.47%, S&P 500 up 0.24%. Tech stocks up 1.1%, communication services down 1.3%. Performance Food Group shares down 6% after reporting earnings miss. AII up 17%, EROC up 20%, BOXL up 69%. NCMI down 31%, UAMY down 22%, STRO down 16%. Oil down 0.1%, gold up 1.1%. Eurozone mixed, Asian markets close mixed. CPI rises 3.4% year-over-year in July.
Read original at benzinga
AII BOXL EROC NCMI PFGC